经典骨髓增殖性肿瘤的诊断、风险分层与疗效评估
该综述围绕2016年WHO分类中费城染色体阴性经典骨髓增殖性肿瘤(PV、ET、PMF)的诊断标准展开,指出JAK2、CALR、MPL驱动基因突变联合血液学与形态学异常是主要诊断依据,并讨论了驱动基因以外的共突变对表型变异与疾病进展的影响,以及当前基于临床和血液学参数、正在开发纳入遗传数据的预后模型和分子谱分析用于疗效评估的前景。
要点
- PV以红细胞增多伴内源性促红细胞生成素受抑、骨髓全髓系增生和JAK2突变为特征。
- ET主要诊断标准为血小板增多、骨髓巨核细胞增殖及JAK2、CALR或MPL突变。
- PMF以骨髓巨核细胞增殖、网状纤维和/或胶原纤维化及JAK2、CALR或MPL突变为特征。
核心结论
- 费城染色体阴性经典骨髓增殖性肿瘤包括PV、ET和PMF,2016年WHO分类修订纳入了这些疾病的新诊断标准。
- JAK2、CALR和MPL三个驱动基因的体细胞突变与血液学和形态学异常相结合是主要诊断标准。
- 骨髓增殖性肿瘤的基因组格局比最初认为的更复杂,驱动基因以外的多个突变基因参与表型变异、表型转变和向更具侵袭性疾病进展。
研究设计与样本
- 综述,围绕2016年WHO造血和淋巴组织肿瘤分类修订版中PV、ET和PMF的诊断标准、风险分层与疗效评估进行论述。
主要发现
- PV以红细胞增多伴内源性促红细胞生成素产生受抑、骨髓全髓系增生和JAK2突变为特征。
- ET的主要诊断标准为血小板增多、骨髓巨核细胞增殖以及JAK2、CALR或MPL突变的存在。
- PMF以骨髓巨核细胞增殖、网状纤维和/或胶原纤维化以及JAK2、CALR或MPL突变的存在为特征。
- 纤维化前骨髓纤维化代表骨髓纤维化的早期阶段,以粒细胞/巨核细胞增殖和骨髓缺乏网状纤维化为特征。
- 共突变的髓系肿瘤抑制基因促成表型变异、表型转变和向更具侵袭性疾病进展。
关键数值与推荐
- PV诊断标准包括红细胞增多伴内源性促红细胞生成素产生受抑、骨髓全髓系增生和JAK2突变。
- ET主要诊断标准为血小板增多、骨髓巨核细胞增殖及JAK2、CALR或MPL突变。
- PMF诊断标准包括骨髓巨核细胞增殖、网状纤维和/或胶原纤维化及JAK2、CALR或MPL突变。
- 纤维化前骨髓纤维化以粒细胞/巨核细胞增殖和骨髓缺乏网状纤维化为特征。
临床怎么用
- 当前预后模型主要基于临床和血液学参数。
- 纳入遗传数据的创新模型正在为临床和试验环境开发。
- 从前景看,骨髓增殖性肿瘤的分子谱分析可能有助于准确评估和监测靶向突变克隆的创新药物的疗效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 revision of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues includes new criteria for the diagnosis of these disorders. Somatic mutations in the 3 driver genes, that is, JAK2, CALR, and MPL, represent major diagnostic criteria in combination with hematologic and morphological abnormalities. PV is characterized by erythrocytosis with suppressed endogenous erythropoietin production, bone marrow panmyelosis, and JAK2 mutation. Thrombocytosis, bone marrow megakaryocytic proliferation, and presence of JAK2, CALR, or MPL mutation are the main diagnostic criteria for ET. PMF is characterized by bone marrow megakaryocytic proliferation, reticulin and/or collagen fibrosis, and presence of JAK2, CALR, or MPL mutation. Prefibrotic myelofibrosis represents an early phase of myelofibrosis, and is characterized by granulocytic/megakaryocytic proliferation and lack of reticulin fibrosis in the bone marrow. The genomic landscape of MPNs is more complex than initially thought and involves several mutant genes beyond the 3 drivers. Comutated, myeloid tumor-suppressor genes contribute to phenotypic variability, phenotypic shifts, and progression to more aggressive disorders. Patients with myeloid neoplasms are at variable risk of vascular complications, including arterial or venous thrombosis and bleeding. Current prognostic models are mainly based on clinical and hematologic parameters, but innovative models that include genetic data are being developed for both clinical and trial settings. In perspective, molecular profiling of MPNs might also allow for accurate evaluation and monitoring of response to innovative drugs that target the mutant clone.
引用
- Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2016. PMID: 28028026. doi:10.1182/blood-2016-10-695957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。